Review
BibTex RIS Cite

Kontrast Ajanlar; Farmakolojik Özellikleri, Genel Advers Reaksiyonları ve İlaç Etkileşimleri

Year 2020, Volume: 53 Issue: 1, 61 - 67, 31.03.2020

Özlem Çelik Aydın Sonay Aydın Hakkı Güney

https://doi.org/10.20492/aeahtd.660381

Abstract

Kontrast ajanlar, genel radyoloji pratiğinde sıklıkla kullanılmaktadırlar. Kontrast ajanları temel olarak iyotlu kontrast ajanları ve gadolinyum bazlı kontrast ajanları olarak ayrılırlar. Bu derlemede amaç, genel kontrast ajanlarının temel farmakolojik özelliklerini, uygulama sonrasında görülen advers reaksiyonları ve ilaç etkileşimlerini özetlemektir.
Contrast agents are commonly used in general radiological practice. Contrast agents are classified into two main groups: iodinated contrast agents and gadolinium based ones. In this review, we aim to summarize the pharmacological properties of contrast agents, their adverse reactions and drug interactions.
Keywords: Radiocontrast, Iodine, Gadolinium, Adverse reaction

Keywords

Radyokontrast İyot Gadolinyum Advers Reaksiyon

References

  • 1. Christiansen C. X-ray contrast media--an overview. Toxicology. 2005;209(2):185-7.
  • 2. Dickinson MC, Kam PC. Intravascular iodinated contrast media and the anaesthetist. Anaesthesia. 2008;63(6):626-34.
  • 3. Singh J, Daftary A. Iodinated contrast media and their adverse reactions. Journal of nuclear medicine technology. 2008;36(2):69-74; quiz 6-7.
  • 4. Pasternak JJ, Williamson EE. Clinical pharmacology, uses, and adverse reactions of iodinated contrast agents: a primer for the non-radiologist. Mayo Clinic proceedings. 2012;87(4):390-402.
  • 5. Spampinato MV, Abid A, Matheus MG. Current Radiographic Iodinated Contrast Agents. Magnetic resonance imaging clinics of North America. 2017;25(4):697-704.
  • 6. Boyd B, Zamora CA, Castillo M. Managing Adverse Reactions to Contrast Agents. Magnetic resonance imaging clinics of North America. 2017;25(4):737-42.
  • 7. Ramalho J, Semelka RC, Ramalho M, Nunes RH, AlObaidy M, Castillo M. Gadolinium-Based Contrast Agent Accumulation and Toxicity: An Update. AJNR American journal of neuroradiology. 2016;37(7):1192-8.
  • 8. Hao D, Ai T, Goerner F, Hu X, Runge VM, Tweedle M. MRI contrast agents: basic chemistry and safety. Journal of magnetic resonance imaging : JMRI. 2012;36(5):1060-71.
  • 9. Todd DJ, Kay J. Gadolinium-Induced Fibrosis. Annual review of medicine. 2016;67:273-91.
  • 10. Ramalho M, Ramalho J. Gadolinium-Based Contrast Agents: Associated Adverse Reactions. Magnetic resonance imaging clinics of North America. 2017;25(4):755-64.
  • 11. Layne KA, Dargan PI, Archer JRH, Wood DM. Gadolinium deposition and the potential for toxicological sequelae - A literature review of issues surrounding gadolinium-based contrast agents. British journal of clinical pharmacology. 2018;84(11):2522-34.
  • 12. Beckett KR, Moriarity AK, Langer JM. Safe Use of Contrast Media: What the Radiologist Needs to Know. Radiographics : a review publication of the Radiological Society of North America, Inc. 2015;35(6):1738-50.
  • 13. Bettmann MA. Frequently asked questions: iodinated contrast agents. Radiographics : a review publication of the Radiological Society of North America, Inc. 2004;24 Suppl 1:S3-10.
  • 14. Perazella MA. Gadolinium-contrast toxicity in patients with kidney disease: nephrotoxicity and nephrogenic systemic fibrosis. Current drug safety. 2008;3(1):67-75.
  • 15. Mamoulakis C, Tsarouhas K, Fragkiadoulaki I, Heretis I, Wilks MF, Spandidos DA, et al. Contrast-induced nephropathy: Basic concepts, pathophysiological implications and prevention strategies. Pharmacology & therapeutics. 2017;180:99-112.
  • 16. Persson PB, Hansell P, Liss P. Pathophysiology of contrast medium-induced nephropathy. Kidney international. 2005;68(1):14-22.
  • 17. Caschera L, Lazzara A, Piergallini L, Ricci D, Tuscano B, Vanzulli A. Contrast agents in diagnostic imaging: Present and future. Pharmacological research. 2016;110:65-75.
  • 18. Swaminathan S. Gadolinium toxicity: Iron and ferroportin as central targets. Magnetic resonance imaging. 2016;34(10):1373-6.
  • 19. Shah AH, Olivero JJ. Gadolinium-Induced Nephrogenic Systemic Fibrosis. Methodist DeBakey cardiovascular journal. 2017;13(3):172-3.
  • 20. McDonald RJ, McDonald JS, Kallmes DF, Jentoft ME, Murray DL, Thielen KR, et al. Intracranial Gadolinium Deposition after Contrast-enhanced MR Imaging. Radiology. 2015;275(3):772-82.
  • 21. Wedeking P, Kumar K, Tweedle MF. Dissociation of gadolinium chelates in mice: relationship to chemical characteristics. Magnetic resonance imaging. 1992;10(4):641-8.
  • 22. Kalaiselvan V, Sharma S, Singh GN. Adverse reactions to contrast media: an analysis of spontaneous reports in the database of the pharmacovigilance programme of India. Drug safety. 2014;37(9):703-10.
  • 23. Leone R, Conforti A, Venegoni M, Motola D, Moretti U, Meneghelli I, et al. Drug-induced anaphylaxis : case/non-case study based on an italian pharmacovigilance database. Drug safety. 2005;28(6):547-56.
  • 24. Katayama H, Yamaguchi K, Kozuka T, Takashima T, Seez P, Matsuura K. Adverse reactions to ionic and nonionic contrast media. A report from the Japanese Committee on the Safety of Contrast Media. Radiology. 1990;175(3):621-8.
  • 25. Ryu J, Lee H, Suh J, Yang M, Kang W, Kim E. Differences between Drug-Induced and Contrast Media-Induced Adverse Reactions Based on Spontaneously Reported Adverse Drug Reactions. PloS one. 2015;10(11):e0142418.
  • 26. Webb JA, Thomsen HS, Morcos SK, Members of Contrast Media Safety Committee of European Society of Urogenital R. The use of iodinated and gadolinium contrast media during pregnancy and lactation. European radiology. 2005;15(6):1234-40.
  • 27. Puac P, Rodriguez A, Vallejo C, Zamora CA, Castillo M. Safety of Contrast Material Use During Pregnancy and Lactation. Magnetic resonance imaging clinics of North America. 2017;25(4):787-97.
  • 28. Ray JG, Vermeulen MJ, Bharatha A, Montanera WJ, Park AL. Association Between MRI Exposure During Pregnancy and Fetal and Childhood Outcomes. Jama. 2016;316(9):952-61.
  • 29. Fraum TJ, Ludwig DR, Bashir MR, Fowler KJ. Gadolinium-based contrast agents: A comprehensive risk assessment. Journal of magnetic resonance imaging : JMRI. 2017;46(2):338-53.
  • 30. Morcos SK, Thomsen HS, Exley CM, Members of Contrast Media Safety Committee of European Society of Urogenital R. Contrast media: interactions with other drugs and clinical tests. European radiology. 2005;15(7):1463-8.
  • 31. Kim SH, Lee HK, Han MC. Incompatibility of water-soluble contrast media and intravascular pharmacologic agents. An in vitro study. Investigative radiology. 1992;27(1):45-9.
  • 32. Thomsen HS, Morcos SK. Contrast media and metformin: guidelines to diminish the risk of lactic acidosis in non-insulin-dependent diabetics after administration of contrast media. ESUR Contrast Media Safety Committee. European radiology. 1999;9(4):738-40.
  • 33. Morcos SK, Thomsen HS, Webb JA. Contrast-media-induced nephrotoxicity: a consensus report. Contrast Media Safety Committee, European Society of Urogenital Radiology (ESUR). European radiology. 1999;9(8):1602-13.

Year 2020, Volume: 53 Issue: 1, 61 - 67, 31.03.2020

Özlem Çelik Aydın Sonay Aydın Hakkı Güney

https://doi.org/10.20492/aeahtd.660381

Abstract

References

  • 1. Christiansen C. X-ray contrast media--an overview. Toxicology. 2005;209(2):185-7.
  • 2. Dickinson MC, Kam PC. Intravascular iodinated contrast media and the anaesthetist. Anaesthesia. 2008;63(6):626-34.
  • 3. Singh J, Daftary A. Iodinated contrast media and their adverse reactions. Journal of nuclear medicine technology. 2008;36(2):69-74; quiz 6-7.
  • 4. Pasternak JJ, Williamson EE. Clinical pharmacology, uses, and adverse reactions of iodinated contrast agents: a primer for the non-radiologist. Mayo Clinic proceedings. 2012;87(4):390-402.
  • 5. Spampinato MV, Abid A, Matheus MG. Current Radiographic Iodinated Contrast Agents. Magnetic resonance imaging clinics of North America. 2017;25(4):697-704.
  • 6. Boyd B, Zamora CA, Castillo M. Managing Adverse Reactions to Contrast Agents. Magnetic resonance imaging clinics of North America. 2017;25(4):737-42.
  • 7. Ramalho J, Semelka RC, Ramalho M, Nunes RH, AlObaidy M, Castillo M. Gadolinium-Based Contrast Agent Accumulation and Toxicity: An Update. AJNR American journal of neuroradiology. 2016;37(7):1192-8.
  • 8. Hao D, Ai T, Goerner F, Hu X, Runge VM, Tweedle M. MRI contrast agents: basic chemistry and safety. Journal of magnetic resonance imaging : JMRI. 2012;36(5):1060-71.
  • 9. Todd DJ, Kay J. Gadolinium-Induced Fibrosis. Annual review of medicine. 2016;67:273-91.
  • 10. Ramalho M, Ramalho J. Gadolinium-Based Contrast Agents: Associated Adverse Reactions. Magnetic resonance imaging clinics of North America. 2017;25(4):755-64.
  • 11. Layne KA, Dargan PI, Archer JRH, Wood DM. Gadolinium deposition and the potential for toxicological sequelae - A literature review of issues surrounding gadolinium-based contrast agents. British journal of clinical pharmacology. 2018;84(11):2522-34.
  • 12. Beckett KR, Moriarity AK, Langer JM. Safe Use of Contrast Media: What the Radiologist Needs to Know. Radiographics : a review publication of the Radiological Society of North America, Inc. 2015;35(6):1738-50.
  • 13. Bettmann MA. Frequently asked questions: iodinated contrast agents. Radiographics : a review publication of the Radiological Society of North America, Inc. 2004;24 Suppl 1:S3-10.
  • 14. Perazella MA. Gadolinium-contrast toxicity in patients with kidney disease: nephrotoxicity and nephrogenic systemic fibrosis. Current drug safety. 2008;3(1):67-75.
  • 15. Mamoulakis C, Tsarouhas K, Fragkiadoulaki I, Heretis I, Wilks MF, Spandidos DA, et al. Contrast-induced nephropathy: Basic concepts, pathophysiological implications and prevention strategies. Pharmacology & therapeutics. 2017;180:99-112.
  • 16. Persson PB, Hansell P, Liss P. Pathophysiology of contrast medium-induced nephropathy. Kidney international. 2005;68(1):14-22.
  • 17. Caschera L, Lazzara A, Piergallini L, Ricci D, Tuscano B, Vanzulli A. Contrast agents in diagnostic imaging: Present and future. Pharmacological research. 2016;110:65-75.
  • 18. Swaminathan S. Gadolinium toxicity: Iron and ferroportin as central targets. Magnetic resonance imaging. 2016;34(10):1373-6.
  • 19. Shah AH, Olivero JJ. Gadolinium-Induced Nephrogenic Systemic Fibrosis. Methodist DeBakey cardiovascular journal. 2017;13(3):172-3.
  • 20. McDonald RJ, McDonald JS, Kallmes DF, Jentoft ME, Murray DL, Thielen KR, et al. Intracranial Gadolinium Deposition after Contrast-enhanced MR Imaging. Radiology. 2015;275(3):772-82.
  • 21. Wedeking P, Kumar K, Tweedle MF. Dissociation of gadolinium chelates in mice: relationship to chemical characteristics. Magnetic resonance imaging. 1992;10(4):641-8.
  • 22. Kalaiselvan V, Sharma S, Singh GN. Adverse reactions to contrast media: an analysis of spontaneous reports in the database of the pharmacovigilance programme of India. Drug safety. 2014;37(9):703-10.
  • 23. Leone R, Conforti A, Venegoni M, Motola D, Moretti U, Meneghelli I, et al. Drug-induced anaphylaxis : case/non-case study based on an italian pharmacovigilance database. Drug safety. 2005;28(6):547-56.
  • 24. Katayama H, Yamaguchi K, Kozuka T, Takashima T, Seez P, Matsuura K. Adverse reactions to ionic and nonionic contrast media. A report from the Japanese Committee on the Safety of Contrast Media. Radiology. 1990;175(3):621-8.
  • 25. Ryu J, Lee H, Suh J, Yang M, Kang W, Kim E. Differences between Drug-Induced and Contrast Media-Induced Adverse Reactions Based on Spontaneously Reported Adverse Drug Reactions. PloS one. 2015;10(11):e0142418.
  • 26. Webb JA, Thomsen HS, Morcos SK, Members of Contrast Media Safety Committee of European Society of Urogenital R. The use of iodinated and gadolinium contrast media during pregnancy and lactation. European radiology. 2005;15(6):1234-40.
  • 27. Puac P, Rodriguez A, Vallejo C, Zamora CA, Castillo M. Safety of Contrast Material Use During Pregnancy and Lactation. Magnetic resonance imaging clinics of North America. 2017;25(4):787-97.
  • 28. Ray JG, Vermeulen MJ, Bharatha A, Montanera WJ, Park AL. Association Between MRI Exposure During Pregnancy and Fetal and Childhood Outcomes. Jama. 2016;316(9):952-61.
  • 29. Fraum TJ, Ludwig DR, Bashir MR, Fowler KJ. Gadolinium-based contrast agents: A comprehensive risk assessment. Journal of magnetic resonance imaging : JMRI. 2017;46(2):338-53.
  • 30. Morcos SK, Thomsen HS, Exley CM, Members of Contrast Media Safety Committee of European Society of Urogenital R. Contrast media: interactions with other drugs and clinical tests. European radiology. 2005;15(7):1463-8.
  • 31. Kim SH, Lee HK, Han MC. Incompatibility of water-soluble contrast media and intravascular pharmacologic agents. An in vitro study. Investigative radiology. 1992;27(1):45-9.
  • 32. Thomsen HS, Morcos SK. Contrast media and metformin: guidelines to diminish the risk of lactic acidosis in non-insulin-dependent diabetics after administration of contrast media. ESUR Contrast Media Safety Committee. European radiology. 1999;9(4):738-40.
  • 33. Morcos SK, Thomsen HS, Webb JA. Contrast-media-induced nephrotoxicity: a consensus report. Contrast Media Safety Committee, European Society of Urogenital Radiology (ESUR). European radiology. 1999;9(8):1602-13.
There are 33 citations in total.

Details

Primary Language Turkish
Subjects Health Care Administration
Journal Section Review
Authors

Özlem Çelik Aydın

Sonay Aydın

Hakkı Güney This is me

Publication Date March 31, 2020
Submission Date December 24, 2019
Published in Issue Year 2020 Volume: 53 Issue: 1

Cite

AMA Çelik Aydın Ö, Aydın S, Güney H. Kontrast Ajanlar; Farmakolojik Özellikleri, Genel Advers Reaksiyonları ve İlaç Etkileşimleri. Ankara Eğitim ve Araştırma Hastanesi Tıp Dergisi. March 2020;53(1):61-67. doi:10.20492/aeahtd.660381